Oral Tofacitinib or Betamethasone Pulse: Which Works Better for Unstable Vitiligo with Phototherapy?

Comparative study of oral tofacitinib versus oral betamethasone pulse therapy in patients with unstable vitiligo undergoing phototherapy - NIL

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/05/086388

Enrollment

Registered

2025-05-06

Start date

Unknown

Completion date

Unknown

Last updated

2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Tofacitinib: Oral Tofacitinib 5mg BD for 4 months Control Intervention1: Betamethasone: Oral Betamethasone Pulse Therapy 5mg Twice Weekly for 4 months

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with vitiligo willing to participate in the study. 2. Patients above 10 years and below 50 years

Exclusion criteria

Exclusion criteria: 1. Patients with history of serious infections, transplantation 2. Patients with comorbidities like cardiovascular disease, venous thromboembolism, liver disease, renal disease, malignancies, hematological disorders 3. Patients who are pregnant or planning for pregnancy, lactation, immunocompromised 4. Patients who have recently received a live vaccine 5. Patients on immunosuppresants, hormonal therapy

Design outcomes

Primary

Measure	Time frame
treatment-related adverse events, laboratory safety parameters, and improvement in quality of life.Timepoint: At Baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks	—

Secondary

Measure	Time frame
RepigmentationTimepoint: at 8 weeks, 12 weeks & 16 weeks	—

Countries

India

Contacts

Public ContactDr Manmathee Malekopmath

JJMMC, Davangere

drhcmangala@gmail.com9886075467

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026